Adherence to Antiplatelet Medications among Persistent and Non-Persistent Older Patients with Peripheral Arterial Disease.
adherence
antiplatelet
co-payment
general practitioner
new user
peripheral arterial disease
persistence
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
30 Nov 2021
30 Nov 2021
Historique:
received:
10
11
2021
revised:
23
11
2021
accepted:
26
11
2021
entrez:
24
12
2021
pubmed:
25
12
2021
medline:
25
12
2021
Statut:
epublish
Résumé
Secondary prevention of peripheral arterial disease (PAD) includes administration of antiplatelet agents, and adherence to medication is a requirement for an effective treatment. The aim of this study was to analyse adherence measured using the proportion of days covered (PDC) index separately in persistent and non-persistent patients, and to identify patient- and medication-related characteristics associated with non-adherence in these patient groups. The study cohort of 9178 patients aged ≥ 65 years in whom PAD was diagnosed in 1/-12/2012 included 6146 persistent and 3032 non-persistent patients. Non-adherence was identified as PDC < 80%. Characteristics associated with non-adherence were determined using the binary logistic regression model. In the group of persistent patients, 15.3% of subjects were identified as non-adherent, while among non-persistent patients, 26.9% of subjects were non-adherent to antiplatelet medication. Administration of dual antiplatelet therapy (aspirin and clopidogrel) and a general practitioner as index prescriber were associated with adherence in both patient groups. Our study revealed a relatively high proportion of adherent patients not only in the group of persistent patients but also in the group of non-persistent patients before discontinuation. These results indicate that most non-persistent PAD patients discontinue antiplatelet treatment rapidly after a certain period of adherence.
Identifiants
pubmed: 34944616
pii: biomedicines9121800
doi: 10.3390/biomedicines9121800
pmc: PMC8698509
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Scientific Grant Agency of the Ministry of Education, Science, Research and Sport of the Slovak Republic
ID : VEGA 1/0024/21
Références
Curr Med Res Opin. 2009 Sep;25(9):2303-10
pubmed: 19635045
Br J Clin Pharmacol. 2012 May;73(5):691-705
pubmed: 22486599
J Gerontol A Biol Sci Med Sci. 2018 May 9;73(6):798-805
pubmed: 29360935
J Manag Care Pharm. 2013 Apr;19(3):247-57
pubmed: 23537459
BMJ Open. 2017 Jan 31;7(1):e014287
pubmed: 28143838
Expert Opin Pharmacother. 2020 Sep;21(13):1603-1616
pubmed: 32558590
Lancet. 2013 Oct 19;382(9901):1329-40
pubmed: 23915883
JAMA. 2007 Jul 4;298(1):61-9
pubmed: 17609491
Ann Intern Med. 2018 Jul 3;169(1):30-35
pubmed: 29946690
N Engl J Med. 1992 Feb 6;326(6):381-6
pubmed: 1729621
Cardiovasc Ther. 2017 Apr;35(2):
pubmed: 27957818
Eur Heart J. 2018 Mar 1;39(9):763-816
pubmed: 28886620
Biomedicines. 2021 Oct 29;9(11):
pubmed: 34829807
Eur Heart J. 2018 Jan 7;39(2):119-177
pubmed: 28886621
World J Cardiol. 2021 Sep 26;13(9):381-398
pubmed: 34621485
Int Urol Nephrol. 2020 May;52(5):903-916
pubmed: 32236780
Clin Cardiol. 2014 Aug;37(8):505-13
pubmed: 24797884
BMC Fam Pract. 2011 Jun 26;12:59
pubmed: 21703010
Stroke. 2014 Jul;45(7):2160-236
pubmed: 24788967
Biomedicines. 2020 Sep 25;8(10):
pubmed: 32992971
J Eval Clin Pract. 2015 Feb;21(1):166-72
pubmed: 25318567
Front Pharmacol. 2021 May 19;12:687549
pubmed: 34093210
Circ Res. 2015 Apr 24;116(9):1509-26
pubmed: 25908725
Biomedicines. 2021 Oct 13;9(10):
pubmed: 34680572
Eur J Clin Pharmacol. 2012 Oct;68(10):1451-60
pubmed: 22476389
Patient Prefer Adherence. 2021 Aug 24;15:1853-1871
pubmed: 34465984
Arterioscler Thromb Vasc Biol. 2020 Mar;40(3):541-553
pubmed: 31996023
Clin Interv Aging. 2018 Nov 28;13:2425-2441
pubmed: 30568434
Drugs Aging. 2014 Oct;31(10):721-30
pubmed: 25212952
Eur J Vasc Endovasc Surg. 2019 Mar;57(3):442-450
pubmed: 30393062
Med Care. 1986 Jan;24(1):67-74
pubmed: 3945130